These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16377413)

  • 21. Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase.
    Xiao X; Wu J; Zhu X; Zhao P; Zhou J; Liu QQ; Zheng L; Zeng M; Liu R; Huang W
    Int J Cancer; 2007 Nov; 121(9):2095-2104. PubMed ID: 17631646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
    Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ZD6474--clinical experience to date.
    Heymach JV
    Br J Cancer; 2005 Jun; 92 Suppl 1(Suppl 1):S14-20. PubMed ID: 15928653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.
    Damiano V; Melisi D; Bianco C; Raben D; Caputo R; Fontanini G; Bianco R; Ryan A; Bianco AR; De Placido S; Ciardiello F; Tortora G
    Clin Cancer Res; 2005 Aug; 11(15):5639-44. PubMed ID: 16061883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145.
    Kovacs MJ; Reece DE; Marcellus D; Meyer RM; Mathews S; Dong RP; Eisenhauer E
    Invest New Drugs; 2006 Nov; 24(6):529-35. PubMed ID: 16791411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.
    Miller KD; Trigo JM; Wheeler C; Barge A; Rowbottom J; Sledge G; Baselga J
    Clin Cancer Res; 2005 May; 11(9):3369-76. PubMed ID: 15867237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
    Yiin JJ; Hu B; Schornack PA; Sengar RS; Liu KW; Feng H; Lieberman FS; Chiou SH; Sarkaria JN; Wiener EC; Ma HI; Cheng SY
    Mol Cancer Ther; 2010 Apr; 9(4):929-41. PubMed ID: 20371720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
    Troiani T; Lockerbie O; Morrow M; Ciardiello F; Eckhardt SG
    Mol Cancer Ther; 2006 Jul; 5(7):1883-94. PubMed ID: 16891475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
    Pakkala S; Ramalingam SS
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S17-23. PubMed ID: 19362942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities.
    Lee DH; Lee MY; Seo Y; Hong HJ; An HJ; Kang JS; Kim HM
    Biomaterials; 2018 Jul; 171():34-45. PubMed ID: 29679794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.
    Holden SN; Eckhardt SG; Basser R; de Boer R; Rischin D; Green M; Rosenthal MA; Wheeler C; Barge A; Hurwitz HI
    Ann Oncol; 2005 Aug; 16(8):1391-7. PubMed ID: 15905307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.
    Brazelle WD; Shi W; Siemann DW
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):836-41. PubMed ID: 16751064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
    Ogino H; Yano S; Kakiuchi S; Yamada T; Ikuta K; Nakataki E; Goto H; Hanibuchi M; Nishioka Y; Ryan A; Sone S
    Cancer Lett; 2008 Jun; 265(1):55-66. PubMed ID: 18364248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.
    Yoshikawa D; Ojima H; Kokubu A; Ochiya T; Kasai S; Hirohashi S; Shibata T
    Br J Cancer; 2009 Apr; 100(8):1257-66. PubMed ID: 19319137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.
    Bianco R; Rosa R; Damiano V; Daniele G; Gelardi T; Garofalo S; Tarallo V; De Falco S; Melisi D; Benelli R; Albini A; Ryan A; Ciardiello F; Tortora G
    Clin Cancer Res; 2008 Aug; 14(16):5069-80. PubMed ID: 18694994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific binding of modified ZD6474 (Vandetanib) monomer and its dimer with VEGF receptor-2.
    Kim YS; Li F; O'Neill BE; Li Z
    Bioconjug Chem; 2013 Nov; 24(11):1937-44. PubMed ID: 24089699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma.
    Shen J; Zheng H; Ruan J; Fang W; Li A; Tian G; Niu X; Luo S; Zhao P
    Br J Cancer; 2013 Jul; 109(1):164-71. PubMed ID: 23799852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
    Langenkamp E; Zwiers PJ; Moorlag HE; Leenders WP; St Croix B; Molema G
    Anticancer Drugs; 2012 Feb; 23(2):161-72. PubMed ID: 22075979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.